Skip to main content

Table 3 Therapy toxicities (>Grade 3)

From: Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study

  Grade 3 Grade 4
Neutropenia 5 (12.5%) 1 (2.5%)
Anemia 6 (15.0%) 0 (0%)
Hypertension 3 (7.5%) 0 (0%)
Anorexia 3 (7.5%) 0 (0%)
Fatigue 3 (7.5%) 0 (0%)
Thromboembolic event 2 (5.0%) 0 (0%)
Jaw osteonecrosis a 2 (5.0%) 0 (0%)
Nausea 1 (2.5%) 0 (0%)
Oral mucositis 1 (2.5%) 0 (0%)
Tumor pain 1 (2.5%) 0 (0%)
Hyponatremia 1 (2.5%) 0 (0%)
Gastrointestinal perforation 0 (0%) 1 (2.5%)
  1. aThese two patients received denosumab